With drug-diagnostic co-development partnerships fueling advances in diagnostic testing for Alzheimer’s, Multiple Sclerosis, cardiovascular disease, rare genetic disorders, and cancer, 2025 is poised as a critical year for Europe’s precision medicine community. However, developing, clinically validating, regulatory filing and commercialising biomarkers and in vitro diagnostics remains no easy feat, as knowledge gaps persist in validating surrogate endpoints, co-developing scalable diagnostic testing workflows and infrastructure, navigating reimbursement pathways, and harmonising drug-diagnostic IVDR-adherence for approval in unmet patient need.

The 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. Serving as your premium connection-making platform, this summit will unite over 200 key European stakeholders to accelerate precision drugs from discovery through to commercialisation for patients in need.

Event link here.